June 24, 2021Open Access

Long-term survival in multiresistant metastatic choriocarcinoma after pembrolizumab treatment: A case report

Key Points

Key points are not available for this paper at this time.

Abstract

•Checkpoint inhibitor therapy affecting PD-L1 as treatment for advanced solid tumors.•Success in trial pembrolizumab therapy in multiresistant metastatic choriocarcinoma.•Long-term remission after pembrolizumab therapy in multiresistant choriocarcinoma.•Only six reported cases, one with comparable follow-up and outcome.

Read Full Paperexternally

AIに質問

Bookmark

View Full Paper

Cite This Study

Paspalj et al. (Thu,) studied this question.

synapsesocial.com/papers/69d8f28da6384138a5d17d32 https://doi.org/https://doi.org/10.1016/j.gore.2021.100817

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Choriocarcinoma and partial hydatidiform moles2000 · 418 citations
2[Preliminary study of PD-1 inhibitor in the treatment of drug-resistant recurrent gestational trophoblastic neoplasia].2020 · 11 citations
3A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia2007 · 111 citations
4Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole2010 · 806 citations
5A critical role for the programmed death ligand 1 in fetomaternal tolerance2005 · 428 citations

AIに質問

Bookmark

View Full Paper